MedTrace Logo

Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects

NCT00689559 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2009-07-02

No results posted yet for this study

Summary

The purpose of the study is to evaluate if AZD3480 and warfarin interact with each other or not, i.e. show the same or altered plasma concentration profiles when co-administered compared to administered alone.

Conditions

Interventions

DRUG

AZD3480

AZD3480 capsules qd, oral, 22 days

DRUG

Placebo

Placebo qd, 12 days

DRUG

Aripiprazole

single dose on day 5

Sponsors & Collaborators

Principal Investigators

  • Lennart Jeppsson · AstraZeneca R&D, Södertälje, Sweden

  • Ctril Clarke, MD · ICON Development Solutions UK

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Completion
2009-04-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00689559 on ClinicalTrials.gov